Abstract
Alzheimers disease (AD) is a devastating disorder that leads to memory loss and dementia. Neurodegeneration of cholinergic neurons in the septum and other basal forebrain areas is evident in early stages of AD. Glutamatergic neurons are also affected early in AD. In these stages, amyloid-β-peptide (Aβ) plaques are present in the hippocampus and other cortices but not in the basal forebrain, which includes the septum. We postulate that early deposition of hippocampal Aβ damages the axon terminals of cholinergic and glutamatergic septo-hippocampal neurons, leading to their degeneration. To determine the mechanisms underlying septal degeneration, fibrillar Aβ1-40 was injected into the Cornu Ammonis (CA1) hippocampal region of rats. Controls were injected with reverse peptide Aβ40-1. A 16% reduction in NeuN+ cells was observed around the injection sites when compared to controls (p < 0.05) one week after injections. Stereology was used to estimate the number of choline acetyl transferase (ChAT), glutamate and glutamic acid decarboxylase 67 (GAD67) immunoreactive septal neurons. Medial septal ChAT and glutamate immunoreactive neurons were reduced 38% and 26%, respectively by hippocampal injections of Aβ1-40 peptide in relation to controls. In contrast, the number of GAD67 inmunoreactive neurons was not significantly reduced. Apoptotic cells were detected in the medial septal region of Aβ1-40 treated animals but not in controls. These results indicate that limited Aβ-induced hippocampal lesions lead to an overall damage of vulnerable septal neuronal populations, most likely by Aβ interaction with septo-hippocampal axon terminals. Thus, axon terminals constitute an important target for novel therapeutics dedicated to control Aβ-induced toxicity.
Keywords: Alzheimer's disease, cholinergic, GABAergic, glutamatergic, hippocampu, medial septum, neurons, intrahippocampal injections, fibrils, ChAT-immunoreactive neurons
Current Alzheimer Research
Title: Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats
Volume: 8 Issue: 8
Author(s): Luis V. Colom, Maria T. Castaneda, Sofia Hernandez, George Perry, Saul Jaime and Ahmed Touhami
Affiliation:
Keywords: Alzheimer's disease, cholinergic, GABAergic, glutamatergic, hippocampu, medial septum, neurons, intrahippocampal injections, fibrils, ChAT-immunoreactive neurons
Abstract: Alzheimers disease (AD) is a devastating disorder that leads to memory loss and dementia. Neurodegeneration of cholinergic neurons in the septum and other basal forebrain areas is evident in early stages of AD. Glutamatergic neurons are also affected early in AD. In these stages, amyloid-β-peptide (Aβ) plaques are present in the hippocampus and other cortices but not in the basal forebrain, which includes the septum. We postulate that early deposition of hippocampal Aβ damages the axon terminals of cholinergic and glutamatergic septo-hippocampal neurons, leading to their degeneration. To determine the mechanisms underlying septal degeneration, fibrillar Aβ1-40 was injected into the Cornu Ammonis (CA1) hippocampal region of rats. Controls were injected with reverse peptide Aβ40-1. A 16% reduction in NeuN+ cells was observed around the injection sites when compared to controls (p < 0.05) one week after injections. Stereology was used to estimate the number of choline acetyl transferase (ChAT), glutamate and glutamic acid decarboxylase 67 (GAD67) immunoreactive septal neurons. Medial septal ChAT and glutamate immunoreactive neurons were reduced 38% and 26%, respectively by hippocampal injections of Aβ1-40 peptide in relation to controls. In contrast, the number of GAD67 inmunoreactive neurons was not significantly reduced. Apoptotic cells were detected in the medial septal region of Aβ1-40 treated animals but not in controls. These results indicate that limited Aβ-induced hippocampal lesions lead to an overall damage of vulnerable septal neuronal populations, most likely by Aβ interaction with septo-hippocampal axon terminals. Thus, axon terminals constitute an important target for novel therapeutics dedicated to control Aβ-induced toxicity.
Export Options
About this article
Cite this article as:
V. Colom Luis, T. Castaneda Maria, Hernandez Sofia, Perry George, Jaime Saul and Touhami Ahmed, Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats, Current Alzheimer Research 2011; 8 (8) . https://dx.doi.org/10.2174/156720511798192763
DOI https://dx.doi.org/10.2174/156720511798192763 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more
Leading Alzheimer Disease Prevention with Precision Health Strategies.
The rising number of patients with Alzheimer’s disease (AD) is a concerning reality in our society. Despite tremendous public-private efforts, finding an appropriate treatment for Alzheimer’s disease prevention has not been successful. One of the reasons behind this failure is the urge to find “a treatment that fits all sizes”, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Peripheral Blood Adipokines and Insulin Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analysis
Current Alzheimer Research Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Memory and Consciousness in Alzheimers Disease
Current Alzheimer Research T2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis
Current Medical Imaging Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia
Current HIV Research Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Oral and Written Naming in Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Medial Temporal Lobe Volumes in Amnestic Mild Cognitive Impairment and Late-life Depression: Research Synthesis
Current Psychiatry Reviews Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Myokines in Myogenesis and Health
Recent Patents on Biotechnology Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
Current Pharmaceutical Design